Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alzheimer's disease
Alzheimer's disease
FDA advisers vote against Biogen's Alzheimer's drug, leaving its future in doubt
Biopharma Dive
Fri, 11/6/20 - 08:46 pm
Biogen
aducanumab
FDA
advisory panels
Alzheimer's disease
The FDA's insider review on aducanumab was all about politics, not science, and it threatens patients and the biopharma industry alike
Endpoints
Fri, 11/6/20 - 10:19 am
FDA
Biogen
aducanumab
Alzheimer's disease
FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Stat
Wed, 11/4/20 - 10:50 am
Biogen
aducanumab
Alzheimer's disease
FDA
advisory panels
The meeting that could change Alzheimer's treatment
BioSpace
Tue, 11/3/20 - 09:44 pm
Biogen
aducanumab
Alzheimer's disease
FDA
Biogen's reprieve as critic recused from aducanumab panel, but analysts still read rejection in the tea leaves
Fierce Biotech
Tue, 11/3/20 - 10:59 am
Biogen
aducanumab
FDA
advisory panel
Alzheimer's disease
Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease
Pharmaceutical Business Review
Tue, 11/3/20 - 10:54 am
Neuraly
NLY01
clinical trials
Alzheimer's disease
Aducanumab’s day of reckoning approaches
EP Vantage
Fri, 10/23/20 - 10:29 am
Biogen
earnings
aducanumab
FDA
Alzheimer's disease
IBM and Pfizer Believe Machine Learning Can Predict Alzheimer’s Risk
BioSpace
Thu, 10/22/20 - 11:21 pm
Pfizer
IBM
artificial intelligence
machine learning
diagnostics
Alzheimer's disease
A Big Alzheimer's Drug Study Is Proceeding Cautiously, Despite The Pandemic
NPR
Tue, 10/20/20 - 10:34 am
clinical trials
Alzheimer's disease
pandemic
COVID-19
Biogen Alzheimer's Drug Headed For Unfavorable Vote, Says An Analyst's Mock Panel
Investors Business Daily
Mon, 10/19/20 - 10:53 am
Biogen
aducanumab
Alzheimer's disease
FDA
analysts
advisory panels
mock advisory panels
Biogen's all-important Alzheimer's drug enters the review gauntlet
BioPharma Dive
Tue, 09/29/20 - 11:38 pm
Biogen
FDA
aducanumab
Alzheimer's disease
Fourth-quarter events to watch for big pharma
EP Vantage
Mon, 09/28/20 - 10:34 pm
COVID-19
clinical trials
AstraZeneca
Gilead Sciences
Takeda
GSK
Roche
Alzheimer's disease
Bristol-Myers Squibb
Pfizer
Eli Lilly
Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved
Fierce Biotech
Wed, 09/23/20 - 10:46 am
Roche
AC Immune
Alzheimer's disease
semorinemab
Seattle-based Athira, aiming for tough Alzheimer's and Parkinson's targets, raises $204M fo
Endpoints
Fri, 09/18/20 - 10:58 am
Athira Pharma
IPOs
Alzheimer's disease
Parkinson's Disease
Cassava Sciences Announces Positive Results In Phase 2 Trial Of New Alzheimer’s Drug
Forbes
Mon, 09/14/20 - 10:25 am
Cassava Sciences
clinical trials
Alzheimer's disease
sumifilam
An old Vertex drug gets new life as an Alzheimer's treatment, but human studies still far off
Endpoints
Fri, 09/11/20 - 11:06 am
Vertex Pharmaceuticals
Alzheimer's disease
VX-765
Athira Aims for the Nasdaq to Advance Alzheimer’s Drug to Phase 2 Tests
Xconomy
Thu, 08/27/20 - 10:25 pm
Athira Pharma
Alzheimer's disease
clinical trials
ATH-1017
Alzheon returns, with a $47 million NIH grant and one last shot at a pivotal PhIII Alzheimer’s success
Endpoints
Thu, 08/20/20 - 10:43 am
Alzheon
NIH
grants
Alzheimer's disease
ALZ-801
Biogen nabs speedy FDA review for controversial Alzheimer’s drug
Fierce Biotech
Fri, 08/7/20 - 11:00 am
Biogen
aducanumab
Eisai
FDA
Alzheimer's disease
priority review
AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts
Fierce Biotech
Tue, 08/4/20 - 11:07 am
AbbVie
Alzheimer's disease
Parkinson's Disease
Voyager Therapeutics
Pages
« first
‹ previous
…
19
20
21
22
23
24
25
26
27
…
next ›
last »